- Home
- AU vs RDY Comparison
AU vs RDY Comparison
Compare AU & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- RDY
- Stock Information
- Founded
- AU 1944
- RDY 1984
- Country
- AU United States
- RDY India
- Employees
- AU N/A
- RDY N/A
- Industry
- AU Precious Metals
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- AU Basic Materials
- RDY Health Care
- Exchange
- AU Nasdaq
- RDY Nasdaq
- Market Cap
- AU 10.3B
- RDY 11.9B
- IPO Year
- AU 1972
- RDY N/A
- Fundamental
- Price
- AU $24.00
- RDY $14.68
- Analyst Decision
- AU Hold
- RDY Buy
- Analyst Count
- AU 5
- RDY 1
- Target Price
- AU $31.75
- RDY $17.00
- AVG Volume (30 Days)
- AU 4.8M
- RDY 1.4M
- Earning Date
- AU 11-07-2024
- RDY 01-28-2025
- Dividend Yield
- AU 0.91%
- RDY 3.97%
- EPS Growth
- AU N/A
- RDY 4.63
- EPS
- AU 1.34
- RDY 0.76
- Revenue
- AU $5,299,000,000.00
- RDY $3,579,112,656.00
- Revenue This Year
- AU $31.43
- RDY $13.39
- Revenue Next Year
- AU $21.09
- RDY $8.35
- P/E Ratio
- AU $18.30
- RDY $19.23
- Revenue Growth
- AU 17.78
- RDY 12.37
- 52 Week Low
- AU $15.80
- RDY $13.26
- 52 Week High
- AU $32.57
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- AU 39.78
- RDY 56.04
- Support Level
- AU $23.47
- RDY $14.45
- Resistance Level
- AU $27.22
- RDY $14.85
- Average True Range (ATR)
- AU 0.60
- RDY 0.16
- MACD
- AU -0.07
- RDY 0.08
- Stochastic Oscillator
- AU 12.27
- RDY 90.91
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.